Noxopharm Ltd has released a press release.
Appendix 4E and Audited Financial Statements FY19
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- More Evidence that Veyonda Enhances RT in Prostate Cancer
- NOX Receives FY19 Federal Government R&D Tax Rebate
- Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
- Noxopharm August 2019 Corporate Presentation
- NOX Announces AU$26 Million Funding Facility
Later from Noxopharm
- Veyonda and Radiotherapy Profiled at Key Oncology Meeting
- Further Review Shows Major Clinical Benefits from Veyonda
- Potential Fundamental Change in Treatment of Brain Cancer
- Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
- Dr Graham Kelly to Assume CEO Role
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm